Dec 29 (Reuters) - Pfizer Inc:
* PFIZER ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF HEMOPHILIA B GENE THERAPY CANDIDATE
* PFIZER - BENEGENE-2 STUDY FOR TREATMENT OF ADULT MALES WITH MODERATELY SEVERE TO SEVERE HEMOPHILIA B MET ITS PRIMARY ENDPOINT
* PFIZER - FIDANACOGENE ELAPARVOVEC WAS GENERALLY WELL-TOLERATED, WITH A SAFETY PROFILE CONSISTENT WITH PHASE 1/2 RESULTS
* PFIZER - KEY SECONDARY ENDPOINTS DEMONSTRATED A 78% REDUCTION IN TREATED ABR AND A 92% REDUCTION IN ANNUALIZED INFUSION RATE Further company coverage: